Terry J. Rosen Ph.D.
Net Worth

Last updated:

What is Terry J. Rosen Ph.D. net worth?

The estimated net worth of Dr. Terry J. Rosen Ph.D. is at least $5,674,518 as of 16 Dec 2022. He owns shares worth $2,373,295 as insider, has earned $1,013,483 from insider trading and has received compensation worth at least $2,287,740 in Arcus Biosciences, Inc..

What is the salary of Terry J. Rosen Ph.D.?

Dr. Terry J. Rosen Ph.D. salary is $326,820 per year as Co-Founder, Chairman & Chief Executive Officer in Arcus Biosciences, Inc..

How old is Terry J. Rosen Ph.D.?

Dr. Terry J. Rosen Ph.D. is 65 years old, born in 1960.

What stocks does Terry J. Rosen Ph.D. currently own?

As insider, Dr. Terry J. Rosen Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Arcus Biosciences, Inc. (RCUS) Co-Founder, Chairman & Chief Executive Officer 242,173 $9.8 $2,373,295

What does Arcus Biosciences, Inc. do?

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.

RCUS logo
RCUS
Arcus Biosciences, Inc.
$9.8

Terry J. Rosen Ph.D. insider trading

Arcus Biosciences, Inc.

Dr. Terry J. Rosen Ph.D. has made 13 insider trades between 2018-2022, according to the Form 4 filled with the SEC. Most recently he sold 10,983 units of RCUS stock worth $336,739 on 16 Dec 2022.

The largest trade he's ever made was exercising 66,666 units of RCUS stock on 19 Mar 2018. As of 16 Dec 2022 he still owns at least 242,173 units of RCUS stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 10,983 $30.66 $336,739
Sale
Common Stock 2,060 $31.23 $64,334
Sale
Common Stock 3,252 $22.29 $72,487
Sale
Common Stock 1,361 $21.71 $29,547
Sale
Common Stock 4,241 $20.72 $87,874
Sale
Common Stock 1,065 $41.42 $44,117
Sale
Common Stock 653 $38.79 $25,329
Sale
Common Stock 417 $39.67 $16,543
Sale
Common Stock 808 $40.57 $32,783
Sale
Common Stock 619 $40.46 $25,043
Sale
Common Stock 1,680 $39.59 $66,515
Sale
Common Stock 4,863 $23.68 $115,156
Sale
Common Stock 3,968 $24.45 $97,018
Purchase
Common Stock 32,050 $23.38 $749,393
Purchase
Common Stock 11,655 $21.44 $249,907
Purchase
Common Stock 2,380 $7.95 $18,928
Purchase
Common Stock 19,358 $7.93 $153,412
Purchase
Common Stock 25,770 $7.75 $199,821
Purchase
Common Stock 15,770 $8.16 $128,746
Purchase
Common Stock 10,650 N/A N/A
Purchase
Common Stock 7,957 N/A N/A
Purchase
Common Stock 7,957 $14.7 $116,984
Purchase
Common Stock 4,954 N/A N/A
Purchase
Common Stock 2,133 N/A N/A
Purchase
Common Stock 2,202 N/A N/A
Purchase
Common Stock 2,790 N/A N/A
Purchase
Common Stock 1,301 N/A N/A
Purchase
Common Stock 4,800 N/A N/A
Purchase
Common Stock 8,932 N/A N/A
Purchase
Common Stock 13,300 N/A N/A
Purchase
Common Stock 6,169 N/A N/A
Purchase
Common Stock 3,279 N/A N/A
Purchase
Common Stock 2,550 N/A N/A
Purchase
Common Stock 4,100 N/A N/A
Purchase
Common Stock 66,666 N/A N/A

Arcus Biosciences key executives

Arcus Biosciences, Inc. executives and other stock owners filed with the SEC:

  • Dr. Terry J. Rosen Ph.D. (65) Co-Founder, Chairman & Chief Executive Officer
  • Ms. Jennifer Jarrett M.B.A. (54) Chief Operating Officer & Director